We aim to map individual aging profiles, represented as trajectories of functional decline in each organ system. To achieve this, we will combine multi-omic profiles with medical records. By applying methods from systems biology, machine learning analyses, and artificial intelligence algorithms, we will identify the primary drivers of degeneration in each organ. This approach will allow us to generate novel predictors that can be used to guide clinical intervention.
We are investigating whether delivering miRNA into aging cells can modulate gene expression and rejuvenate cells. Our research is focused on identifying miRNA that control the processes of aging.
Existing gene therapy vehicles are limited in their ability to deliver large genetic loads. This poses a major challenge to treating and reversing aging, due to the complexity of aging-related diseases and the large number of genes that may need to be modulated to fight aging. Centaura is investing in cutting-edge technologies to efficiently and stably deliver large-scale gene therapy that will retune the expression of multiple genes. This will enable scientists to rapidly and precisely test anti-aging gene therapies in human cells and animal models.
Transposable elements are genomic "parasites" that constitute approximately 30% of mammalian genomes. These elements are repressed in younger cells, but become active as cells age. Their activation promotes aging and aging‑related inflammation.
At Centaura, we are investigating ways to deactivate transposable elements and prevent cell aging.